Drug
Edp 235
Edp 235: highest development phase Phase 2, developed by Enanta Pharmaceuticals. 4 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Enanta Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| EDP-235 NCT05616728 | Phase 2 | COVID-19 |
| EDP-235 NCT05594602 | Phase 1 | COVID-19 |
| EDP-235 NCT05246878 | Phase 1 | SARS CoV 2 Infection |
| EDP-235 NCT05594615 | Phase 1 | COVID-19 |
Latest
No recent events.
Follow Edp 235 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.